Dr. Chengbin Wu is the founder and Chief Executive Officer of EpimAb Biotherapeutics. Before founding EpimAb, he was Chief Scientific Officer and President of R&D at 3Sbio, a leading China-based biopharmaceutical company focusing on developing therapeutic antibodies to treat various diseases. Previously he was the Senior VP Biologics at Shanghai ChemPartner, where he established comprehensive biologics R&D capabilities. Before that he was a Volwiler Associate Fellow at Abbvie, USA. Dr. Wu has extensive experience in engineering and development of therapeutic antibodies. He is also the primary inventor of the FIT-Ig® technology, a new bispecific antibody platform for developing next generation biologics therapies. Dr. Wu received his Ph.D. degree from the University of Georgia in the US, and postdoctoral training at Harvard Medical School.

Dr. Stephan Lensky joined EpimAb early on and is responsible for EpimAb’s strategy and business development, bring in more than 15 years of business development experience with multi-national pharmaceutical companies.  Previously he headed the Corporate Department for Strategic Transactions & Alliance Management at Boehringer Ingelheim GmbH, responsible for the negotiation and management of all strategic transactions of Prescription Medicines (PM) Business.  Prior to that, he led a group at Bayer responsible for all commercial licenses in Europe and the Emerging Markets. Dr. Lensky holds a Ph.D. in Chemistry, and is a member of the BioFIT Steering Committee since 2014.

Dr. Yonghong Zhu is responsible for the overall strategy of translational medicine and clinical development at EpimAb.  Previously he was the Chief Medical Officer at Maxinovel Pharmaceuticals. Dr Zhu has worked in the pharmaceutical industry for many years, including career stints at the US R&D centers of Roche, Genentech, and Takeda, holding positions with increased responsibilities such as biomarker & experimental medicine leader, senior clinical scientist, and senior medical director. Prior to his experience at large multi-national pharmaceutical/biotech companies, he was a biotech scientist working on translational biology and preclinical research at Sunesis and Osel in the San Francisco Bay Area.  After coming to China in 2017, Dr. Zhu first established a clinical development group at Shanghai Henlius, leading the late stage clinical development of multiple biosimilars and trial designs of innovative drugs in oncology, immunology, and ophthalmology therapeutic areas. Then he joined Roche Pharma-Shanghai Innovation Center as global clinical development program & translational medicine dual leader, focusing on early-stage clinical research in immunology, infectious diseases and ophthalmology, leading the overall development of several new molecules across different therapeutic areas and international multi-center clinical trials. 

Dr. Zhu graduated from Nanjing University School of Medicine. He received training from the first seven-year medical program in China. After practicing medicine for a few years, he studied at the University of Rochester School of Medicine and Dentistry, New York, USA, and received a Ph.D. in Microbiology and Immunology. Later he completed industrial postdoctoral training in discovery research at the immunology company DNAX (now part of Merck).

Dr. David (Xinyi) Gu is responsible for financial operation and financing strategies at EpimAb.  Previously, he was a Senior Analyst at Millennium Management overseeing public investments in global pharmaceutical and biotechnology companies. Before that, Dr. Gu was a Vice President and Global Pharmaceutical Equity Research Analyst at Jefferies LLC, where he was responsible for covering global large-cap pharmaceutical companies across multiple therapeutic areas, evaluating companies for initial and secondary public offerings, and advising clients on investment strategy and business development. Prior to Jefferies, Dr. Gu was a management consultant at McKinsey & Company, and also held equity research positions at Wells Fargo Securities.Dr. Gu holds a Ph.D. in Pharmaceutical Sciences from the University of Michigan, and graduated summa cum laude with a Bachelor of Science degree in Biochemistry from the University of Illinois at Urbana-Champaign.